Indigo Diabetes Announces First Participant Enrolled in the SHINE Clinical Trial

BELGIUM – Ghent, September 29,…

Dr Jeanne Bolger to chair Board of Directors of Belgium-based vaccine technology company AstriVax

Dr Jeanne Bolger brings over…

Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bordeaux to Develop Gene Therapy Programs Targeting Protein Degradation in Neurodegenerative Disorders

Coave Therapeutics to Collaborate with…

Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD

Minoryx‘s Marketing Authorization Application for…

KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform

KU Leuven spin-off AstriVax raises…

Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium

Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States…

Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding RNABased Lead Candidate CDR132L in Heart Failure Patients PostMyocardial Infarction

Cardior Announces First Patient Dosed…

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén

Immunic, Inc. Strengthens Its Board…

Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy

Minoryx raises €51 million to…

Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

Immunic Announces Start of Patient…